# Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

> **NCT07013747** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 120 (estimated)

## Conditions studied

- Acne

## Interventions

- **BIOLOGICAL:** Acne mRNA vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07013747
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-03
- **Primary completion:** 2029-06-19
- **Final completion:** 2029-06-19
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013747, "Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07013747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*